English

Unicycive Therapeutics, Inc.

EDGAR

UNCY Quarterly report (10-Q) · filed 2026-08-12

28 filing records in this dataset, filed from 2021-05-21 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 675000 USD Source
Revenue: 675000 USD Source

Operating cash flow

-4.44 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -18283000 USD Source
Operating Cash Flow: -13844000 USD Source

Free cash flow

-4.44 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -18283000 USD Source
Operating Cash Flow: -13844000 USD Source
Capital Expenditure: 12000 USD Source
Capital Expenditure: 12000 USD Source

Cash and cash equivalents: 44.2 million uref_858378165 2026-06-30 Source
Exact value

44185000 uref_858378165
Long-term debt including current maturities: Not available
Shares outstanding: 27.9 million uref_1585167401 2026-06-30 Source
Exact value

27855257 uref_1585167401

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

675 thousand USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Revenue: 675000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 675000 USD · 2023-01-01 – 2023-06-30 Source
Revenue: 675000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 675000 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 675000 USD · 2023-01-01 – 2023-06-30 Source
Revenue: 675000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 675000 USD · 2023-01-01 – 2023-09-30 Source

Operating cash flow

-28.7 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -17323000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -8903000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -23285000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -17323000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -31317000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -23285000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -6241000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

16 thousand USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Capital expenditure: 22000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 16000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 22000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 24000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-28.7 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -17323000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -8903000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -23285000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -17323000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -31317000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -23285000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -6241000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 22000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 16000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 22000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 24000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 24000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2023-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 5 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 10.17 million

Prior period

−USD 36.73 million

2024-01-01 – 2024-12-31
Current period

−USD 26.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-26555000 − -36729000 = 10174000 USD

-36729000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-26555000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Year-over-year change in Net income: 10174000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -26555000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#1434623 Filing: 000121390026035903 Input fundies:NetIncome: -36729000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#1434271 Filing: 000121390026035903
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.74 million

Prior period

−USD 28.58 million

2024-01-01 – 2024-12-31
Current period

−USD 31.32 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-31317000 − -28575000 = -2742000 USD

-28575000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-31317000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Year-over-year change in Operating cash flow: -2742000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -31317000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#995177 Filing: 000121390026035903 Input fundies:OperatingCashFlow: -28575000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#994721 Filing: 000121390026035903
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-66.7%

Prior period

USD 72,000

2024-01-01 – 2024-12-31
Current period

USD 24,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

24000 − 72000 = -48000 USD

72000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
24000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Year-over-year change in Capital expenditure: -48000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 24000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#997435 Filing: 000121390026035903 Input fundies:CapitalExpenditure: 72000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#996992 Filing: 000121390026035903
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 675,000 100% of revenue
Operating costs Derived USD 21.45 million 3,178% of revenue
Operating income −USD 20.77 million −3,078% of revenue
Tax, interest and other Derived USD 9.77 million 1,447% of revenue
Net income −USD 30.54 million −4,525% of revenue

Cash

Operating cash flow −USD 18.28 million −2,709% of revenue
Capital expenditure USD 12,000 1.8% of revenue
Free cash flow Derived −USD 18.3 million −2,710% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 1,998% of revenue.
2023 Operating loss: operating costs were 3,178% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	951000	19003000 Derived	-18052000	6000 Derived	-18058000	-15653000 Derived	Source 2022-01-01 – 2022-12-31: 951000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -18052000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -18058000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -15651000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 2000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	675000	21449000 Derived	-20774000	9770000 Derived	-30544000	-18295000 Derived	Source 2023-01-01 – 2023-12-31: 675000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -20774000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -30544000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -18283000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 12000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 675K 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	951000	Revenue: 951000 Open source
20232023-12-31	Revenue	675000	Revenue: 675000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-29% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 951000 Open source
20232023-12-31	Year over year	-29%	Revenue: 675000 Open source Revenue: 951000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3,077.6% 2023

Net margin -4,525% 2023

Free cash flow margin -2,710.4% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-1,898.2%	Operating Income: -18052000 Open source Revenue: 951000 Open source
20232023-12-31	Operating margin	-3,077.6%	Operating Income: -20774000 Open source Revenue: 675000 Open source
20222022-12-31	Net margin	-1,898.8%	Net Income: -18058000 Open source Revenue: 951000 Open source
20232023-12-31	Net margin	-4,525%	Net Income: -30544000 Open source Revenue: 675000 Open source
20222022-12-31	Free cash flow margin	-1,646%	Revenue: 951000 Open source Operating Cash Flow: -15651000 Open source Capital Expenditure: 2000 Open source
20232023-12-31	Free cash flow margin	-2,710.4%	Revenue: 675000 Open source Operating Cash Flow: -18283000 Open source Capital Expenditure: 12000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -18.3M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-15651000	Operating Cash Flow: -15651000 Open source
20232023-12-31	Operating cash flow	-18283000	Operating Cash Flow: -18283000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -18.3M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-15653000	Operating Cash Flow: -15651000 Open source Capital Expenditure: 2000 Open source
20232023-12-31	Free cash flow	-18295000	Operating Cash Flow: -18283000 Open source Capital Expenditure: 12000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2022-12-31	Liabilities / assets	Not reported	No source recorded
2023-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2022-12-31	Current assets / current liabilities	Not reported	No source recorded
2023-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 2.26 million Exact value Exact value: -2264000 USD 2020-01-01 – 2020-12-31: -2264000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Unicycive Therapeutics, Inc. · 2020-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Net Income: -2264000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2264000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390022016384/f10k2021_unicycivethera.htm#1127412 Filing: 000121390022016384 The citation records this snapshot. The page link may show a newer release later.	−USD 1.46 million Exact value Exact value: -1459000 USD 2020-01-01 – 2020-12-31: -1459000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Unicycive Therapeutics, Inc. · 2020-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Operating Cash Flow: -1459000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1459000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390022016384/f10k2021_unicycivethera.htm#821054 Filing: 000121390022016384 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 10.02 million Exact value Exact value: -10017000 USD 2021-01-01 – 2021-12-31: -10017000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Unicycive Therapeutics, Inc. · 2021-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Net Income: -10017000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10017000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024901/f10k2022_unicycive.htm#747407 Filing: 000121390023024901 The citation records this snapshot. The page link may show a newer release later.	−USD 5.77 million Exact value Exact value: -5767000 USD 2021-01-01 – 2021-12-31: -5767000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Unicycive Therapeutics, Inc. · 2021-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Operating Cash Flow: -5767000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5767000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024901/f10k2022_unicycive.htm#759316 Filing: 000121390023024901 The citation records this snapshot. The page link may show a newer release later.	USD 29,000 Exact value Exact value: 29000 USD 2021-01-01 – 2021-12-31: 29000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Unicycive Therapeutics, Inc. · 2021-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Capital Expenditure: 29000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024901/f10k2022_unicycive.htm#760820 Filing: 000121390023024901 The citation records this snapshot. The page link may show a newer release later.	−USD 5.8 million Calculation and evidence -5767000 − 29000 USD Exact free cash flow: -5796000 USD 2021-01-01 – 2021-12-31: -5767000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 29000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Unicycive Therapeutics, Inc. · 2021-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Free cash flow: -5796000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5767000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024901/f10k2022_unicycive.htm#759316 Filing: 000121390023024901 Input fundies:CapitalExpenditure: 29000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390023024901/f10k2022_unicycive.htm#760820 Filing: 000121390023024901 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 18.06 million Exact value Exact value: -18058000 USD 2022-01-01 – 2022-12-31: -18058000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Unicycive Therapeutics, Inc. · 2022-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Net Income: -18058000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18058000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027202/ea0202007-10k_unicy.htm#1195553 Filing: 000121390024027202 The citation records this snapshot. The page link may show a newer release later.	−USD 15.65 million Exact value Exact value: -15651000 USD 2022-01-01 – 2022-12-31: -15651000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Unicycive Therapeutics, Inc. · 2022-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Operating Cash Flow: -15651000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15651000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027202/ea0202007-10k_unicy.htm#853339 Filing: 000121390024027202 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2022-01-01 – 2022-12-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Unicycive Therapeutics, Inc. · 2022-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027202/ea0202007-10k_unicy.htm#854934 Filing: 000121390024027202 The citation records this snapshot. The page link may show a newer release later.	−USD 15.65 million Calculation and evidence -15651000 − 2000 USD Exact free cash flow: -15653000 USD 2022-01-01 – 2022-12-31: -15651000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Unicycive Therapeutics, Inc. · 2022-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Free cash flow: -15653000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15651000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027202/ea0202007-10k_unicy.htm#853339 Filing: 000121390024027202 Input fundies:CapitalExpenditure: 2000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390024027202/ea0202007-10k_unicy.htm#854934 Filing: 000121390024027202 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 30.54 million Exact value Exact value: -30544000 USD 2023-01-01 – 2023-12-31: -30544000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Unicycive Therapeutics, Inc. · 2023-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Net Income: -30544000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30544000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/ea0235049-10k_unicycive.htm#1327775 Filing: 000121390025025828 The citation records this snapshot. The page link may show a newer release later.	−USD 18.28 million Exact value Exact value: -18283000 USD 2023-01-01 – 2023-12-31: -18283000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Unicycive Therapeutics, Inc. · 2023-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Operating Cash Flow: -18283000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18283000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/ea0235049-10k_unicycive.htm#926496 Filing: 000121390025025828 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2023-01-01 – 2023-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Unicycive Therapeutics, Inc. · 2023-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/ea0235049-10k_unicycive.htm#928092 Filing: 000121390025025828 The citation records this snapshot. The page link may show a newer release later.	−USD 18.3 million Calculation and evidence -18283000 − 12000 USD Exact free cash flow: -18295000 USD 2023-01-01 – 2023-12-31: -18283000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Unicycive Therapeutics, Inc. · 2023-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Free cash flow: -18295000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18283000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/ea0235049-10k_unicycive.htm#926496 Filing: 000121390025025828 Input fundies:CapitalExpenditure: 12000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/ea0235049-10k_unicycive.htm#928092 Filing: 000121390025025828 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 36.73 million Exact value Exact value: -36729000 USD 2024-01-01 – 2024-12-31: -36729000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Unicycive Therapeutics, Inc. · 2024-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Net Income: -36729000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36729000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#1434271 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.	−USD 28.58 million Exact value Exact value: -28575000 USD 2024-01-01 – 2024-12-31: -28575000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Unicycive Therapeutics, Inc. · 2024-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Operating Cash Flow: -28575000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28575000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#994721 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.	USD 72,000 Exact value Exact value: 72000 USD 2024-01-01 – 2024-12-31: 72000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Unicycive Therapeutics, Inc. · 2024-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Capital Expenditure: 72000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 72000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#996992 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.	−USD 28.65 million Calculation and evidence -28575000 − 72000 USD Exact free cash flow: -28647000 USD 2024-01-01 – 2024-12-31: -28575000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 72000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Unicycive Therapeutics, Inc. · 2024-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Free cash flow: -28647000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28575000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#994721 Filing: 000121390026035903 Input fundies:CapitalExpenditure: 72000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#996992 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 26.56 million Exact value Exact value: -26555000 USD 2025-01-01 – 2025-12-31: -26555000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Net Income: -26555000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26555000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#1434623 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.	−USD 31.32 million Exact value Exact value: -31317000 USD 2025-01-01 – 2025-12-31: -31317000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Operating Cash Flow: -31317000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31317000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#995177 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.	USD 24,000 Exact value Exact value: 24000 USD 2025-01-01 – 2025-12-31: 24000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Capital Expenditure: 24000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#997435 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.	−USD 31.34 million Calculation and evidence -31317000 − 24000 USD Exact free cash flow: -31341000 USD 2025-01-01 – 2025-12-31: -31317000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 24000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Unicycive Therapeutics, Inc. · 2025-12-31 Unicycive Therapeutics, Inc. (edgar:1766140) Free cash flow: -31341000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:27:33Z Snapshot: 173e07ee4a5a4e52bf2bf21b3bdbb2dedbdf41f848250312583d095bfbde9547 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1766140?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31317000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#995177 Filing: 000121390026035903 Input fundies:CapitalExpenditure: 24000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm#997435 Filing: 000121390026035903 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 1,267 latest values · 1,267 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001766140, 1766140, UNCY, edgar:1766140

Also known as UNICYCIVE THERAPEUTICS, INC., UNICYCIVE THERAPEUTICS, INC., Unicycive Therapeutics, Inc., Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation